Omalizumab

Details

Files

Generic Name:

Omalizumab

Project Status:

Complete

Therapeutic Area:

Chronic idiopathic urticaria

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Call for patient/clinician input open:

August 22, 2014

Brand Name:

Xolair

Project Line:

Reimbursement Review

Project Number:

SR0398-000

Call for patient/clinician input closed:

October 14, 2014

NOC Status at Filing:

Post NOC

Submission Type:

Initial

Indications:

Urticaria, chronic idiopathic

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

May 7, 2015

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Clinical Report View PDF

Pharmacoeconomic Report View PDF

Patient Group Input Submissions View PDF

Last Updated : September 22, 2014